Epizyme, Inc. (EPZM) News

Epizyme, Inc. (EPZM): $1.47

-0.02 (-1.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EPZM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter EPZM News Items

EPZM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EPZM News Highlights

  • EPZM's 30 day story count now stands at 6.
  • Over the past 15 days, the trend for EPZM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • APTX, BEAT and RAMP are the most mentioned tickers in articles about EPZM.

Latest EPZM News From Around the Web

Below are the latest news stories about EPIZYME INC that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Yahoo | August 12, 2022

Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

Yahoo | August 10, 2022

The past five years for Epizyme (NASDAQ:EPZM) investors has not been profitable

Epizyme, Inc. ( NASDAQ:EPZM ) shareholders will doubtless be very grateful to see the share price up 219% in the last...

Yahoo | August 10, 2022

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 9, 2022

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass., August 09, 2022--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update.

Yahoo | August 9, 2022

Mass. M&A activity picks up among life sciences firms

Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.

Yahoo | July 28, 2022

Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More

Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.

Yahoo | June 29, 2022

Epizyme shares soar 60% on acquisition news

French drugmaker Ipsen SA, which four years ago moved its U.S. headquarters to Cambridge, is snapping up the embattled cancer firm Epizyme Inc. for $247 million. Ipsen is paying $1.45 for each share of Epizyme (Nasdaq: EPZM), a 56% premium over where they were at market close on Friday. The company has a market capitalization of $246.5 million.

Yahoo | June 27, 2022

Why Epizyme Stock Is Soaring Today

Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipsen (OTC: IPSEY). Ipsen reportedly agreed to pay $1.45 per share, as well as a milestone-dependent contingent value right (CVR) of $1.00 per share, to acquire the small-cap drugmaker.

Yahoo | June 27, 2022

Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen

Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.

Yahoo | June 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4606 seconds.